Revelation Biosciences (REVB) CEO granted 532,829 RSUs in equity award

Rhea-AI Filing Summary

Revelation Biosciences, Inc. reported an equity grant to its chief executive. CEO and director James Rolke received an award of 532,829 shares of common stock on January 8, 2026, reported at a grant price of $0.90 per share.

The award consists of restricted stock units under the company’s 2021 Equity Incentive Plan. These units are scheduled to vest quarterly over two years from the grant date, meaning portions of the award convert into common shares over time as service-based conditions are met. The filing shows the award is held directly by Mr. Rolke as part of his equity compensation.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Rolke James

(Last) (First) (Middle)

C/O REVELATION BIOSCIENCES, INC.

4660 LA JOLLA VILLAGE DR., SUITE 100

(Street)

SAN DIEGO CA 92122

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
REVELATION BIOSCIENCES, INC. [ REVB ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Executive Officer

3. Date of Earliest Transaction (Month/Day/Year)
01/08/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock								400,660	D
Common Stock(1)	01/08/2026		A		532,829	A	$0.9	933,489	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Restricted Stock Units under the 2021 Equity Incentive Plan. Vests quarterly over two years from the date of grant.

	/s/ J.P. Galda, as attorney-in-fact for James Rolke	01/12/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did REVB report for CEO James Rolke?

The company reported that CEO and director James Rolke received an award of 532,829 shares of common stock on January 8, 2026 as part of his equity compensation.

What type of securities did the REVB CEO receive in this filing?

The filing shows an award of restricted stock units (RSUs) tied to common stock of Revelation Biosciences, Inc.

At what price were the 532,829 Revelation Biosciences shares granted?

The 532,829 shares reported for CEO James Rolke were granted at a price of $0.90 per share.

How do the REVB restricted stock units for the CEO vest?

The restricted stock units vest quarterly over two years from the grant date, according to the filing’s explanation of responses.

Under which plan were the REVB CEO’s restricted stock units granted?

The restricted stock units were granted under Revelation Biosciences’ 2021 Equity Incentive Plan.

Does the filing indicate whether the CEO’s ownership is direct or indirect?

The transaction is reported as direct ownership of common stock by CEO James Rolke.

What is the significance of this REVB Form 4 for investors?

The Form 4 documents a routine equity compensation grant to the CEO, showing ongoing use of the 2021 Equity Incentive Plan to compensate leadership in stock-linked awards.